Founder & CEO, Bradley Burnam, to Ring NASDAQ “Closing Bell” at 4:00 PM ET WESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces that its common stock is scheduled to commence trading today, October 8, 2025, on the Nasdaq Capital Market under ticker... Read More